AUTHORS
Patrick Connor Johnson, MD, Matthew Frigault, MD2, Nora Horick3, Trisha Berger, PhD4, Jacob D. Soumerai, MD5, Julie Haydu, MD, PhD6, Jeremy S. Abramson, MD7, Danielle Bernier8, Lu Huang, PhD9, Myriam Armant, PhD10, Sarah Nikiforow, MD, PhD11, Maxx King12, Marisa Gabrielle Ogier13, Jing Li14, Deshea L. L. Harris, MS15, Maci Schaub, MS16, Estelle Emmanuel-Alejandro, BA17, Kathleen Gallagher, PhD, MSc, BSc18, Marcela V. Maus, MD, PhD19
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
6 Massachusetts General Hospital, Boston, Massachusetts, United States
7 Massachusetts General Hospital, Boston, Massachusetts, United States
8 Massachusetts General Hospital, Boston, Massachusetts, United States
9 Massachusetts General Hospital, Boston, Massachusetts, United States
10 Boston Children's Hospital, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Massachusetts General Hospital, Boston, Massachusetts, United States
13 Massachusetts General Hospital, Boston, Massachusetts, United States
14 Massachusetts General Hospital, Boston, Massachusetts, United States
15 Massachusetts General Hospital, Boston, Massachusetts, United States
16 Massachusetts General Hospital, Boston, Massachusetts, United States
17 Massachusetts General Hospital, Boston, Massachusetts, United States
18 Massachusetts General Hospital, Boston, Massachusetts, United States
19 Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Introduction: Though anti-CD19 CAR-T cell therapy has transformed management of relapsed/refractory B-cell non-Hodgkin lymphomas (NHL), the majority of patients will relapse. Antigen loss is one important mechanism of relapse; dual-targeting CAR-T cells are a potential avenue to improve outcomes. CD79b is highly expressed on most B-cell lymphomas and represents a promising therapeutic target. Preclinical data demonstrated encouraging activity for CD79b-19 tandem CAR-T cells.
Methods: In this first-in-human, open-label, phase I trial, adults with relapsed/refractory B-cell NHL who had progressed on standard therapy received escalating doses of autologous T cells lentivirally transduced with a tandem CAR targeting CD79b and CD19 (fused to CD8α hinge and transmembrane domains, 4-1BB co-stimulatory domain, and CD3zeta). Dose escalation followed a 3+3 model-based design, followed by expansion at the recommended dose. The primary endpoints were safety, dose-limiting toxicities (DLTs), and determination of the recommended phase 2 dose. Secondary endpoints included objective response rate, progression-free survival (PFS), and overall survival (OS). Exploratory objectives included expansion, persistence, phenotype, and functional activity of CAR-T cells. Adverse events were graded according to Common Terminology Criteria for Adverse Events version 5.0, and tumor responses were assessed using the Lugano Classification. Bridging therapy was permitted. The date for data cutoff was 6/4/2026.
Results: Between October 2023 and May 2026, 16 patients were enrolled, of whom 12 successfully received CD79b-19 CAR-T cells following lymphodepleting chemotherapy with 3 days of fludarabine (30 mg/m2/day) and cyclophosphamide (300 mg/m2/day). 1 patient withdrew consent after collection, 1 patient developed rapid disease progression and was unable to receive therapy, and 2 heavily pretreated patients were unable to have cells manufactured. 2 patients received treatment at dose level -1 (3x107 CAR+ T-cells), 9 received treatment at dose level 1 (1x108 CAR+ T-cells), and one patient was infused with a low cell dose via exceptional release due to rapidly progressive and highly refractory disease.
Patients’ median age was 66 years (range: 40-74), with median 4 (range: 2-7) prior lines of therapy (75% with prior anti-CD19 CAR). Histologies included mantle cell lymphoma (58%), large B-cell lymphoma (33%), and marginal zone lymphoma (8%). Most (83%) had advanced stage disease and an elevated LDH (66%); IPI was 1 in 17%, 2 in 33%, and 3-5 in 50% of patients.
The most common treatment-related adverse events included cytokine release syndrome (CRS) (75%), neutropenia (50%), and fatigue (33%). Grade ≥3 treatment-related adverse events occurred in 67% of patients. CRS events (n=9) were grade 1 in 67% (n=6) and grade 2 in 33% (n=3). No cases of grade 3+ CRS occurred. A single grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) event occurred (8%). DLTs occurred in 0 patients. There were no treatment-related deaths, and the maximum tolerated dose was not reached. The recommended phase 2 dose was established as 1x108 CAR+ T-cells.
Among 12 response-evaluable patients, the objective response rate (ORR) was 67%, all of which (67%) were complete responses (CR). In the subset of patients with mantle cell lymphoma (n=7), the ORR was 86%, all of which were CRs (86%). The median follow up was 310 days (range: 24-867). The estimated 6 month, 12 month, and 24 month PFS rates were all 63% (95% confidence interval [CI] 28%-84%). Estimated 6 month, 12 month, and 24 month OS rates were 89% (43%-98%), 89% (43%-98%), and 71% (23-92%), respectively. The median PFS and OS were not reached. Of patients in CR, no patients have progressed to date with median follow up of 10 months (range 1-29 months).
Median vein-to-vein time of infused patients was 29 days (range 23-36 days). Median peak expansion of CAR-T cells was 501 cells/uL blood (range 4.5-21,204), with a median peak expansion of 14 days. 5 out of 6 evaluable patients had detectable CAR-T cells at 6 months post-infusion, and 3 out of 4 evaluable patients had detectable CAR-T cells at 12 months post-infusion.
Conclusion: CD79b-19 tandem CAR-T cells demonstrated a favorable toxicity profile, no dose-limiting toxicities, and encouraging preliminary efficacy in relapsed/refractory B-cell NHL.
DISCLOSURES
Patrick Connor Johnson, MD: Incyte - Research Funding; Novartis - Research Funding; AstraZeneca - Research Funding; Kite - Research Funding; Olira - Research Funding; Medically Home - Research Funding; Leuko Labs - Research Funding; BMS - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony)